Join
Live feed
·
PRReleasevia Quantisnow
Celldex Therapeutics Inc. logo

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

ByQuantisnow·Wall Street's wire, on your screen.
CLDX· Celldex Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CLDX (Celldex Therapeutics Inc.) and more on Quantisnow.